BOSTON--(BUSINESS WIRE)--Kyn Therapeutics, a clinical-stage biotechnology company developing new immunometabolic therapies for treating cancer, today announced that it is expanding its management team with the appointment of Douglas Carlson as its chief financial officer. Mr. Carlson’s most recent role was vice president, commercial operations, corporate strategy & business development at Collegium Pharmaceutical (NASDAQ:COLL), a specialty pharmaceutical company focused on pain management.
“Doug brings nearly two decades of multi-disciplinary experience in the strategic financial management of biotech and healthcare companies. He joins Kyn at a new stage of its growth with the initiation of our EP4 antagonist clinical program and the signing of our global strategic collaboration with Celgene on two other immuno-oncology programs,” said Mark Manfredi, Ph.D., Kyn’s president and chief executive officer. “Doug’s depth of experience in capital raising strategy, operations, finance and commercial planning complements the skills of our existing team and positions us well as we expand our maturing operations focused on delivering novel immunotherapies to people with cancer.”
“Kyn has rapidly shaped an industry-leading team and assembled valuable alliances and a portfolio of differentiated cancer immunotherapies with potential applicability across a broad variety of cancer types,” said Mr. Carlson. “It is an exciting time for Kyn and I welcome the opportunity to join the leadership team and help foster the company’s development.”
Mr. Carlson joined Collegium Pharmaceutical in 2013 and helped oversee the company’s development from a privately-held, clinical-development stage company to a publicly-traded commercial business. At Collegium, Mr. Carlson led corporate strategy, commercial and business development initiatives, including all aspects of strategic decision support and commercial operations. Prior to Collegium, he was senior director, business development at BTG International, a healthcare company focused on specialty pharmaceuticals, interventional medicine and licensing, where he was responsible for global specialty pharmaceutical M&A and licensing. Previously, Mr. Carlson worked at Ovation Pharmaceuticals as director, corporate business development and strategy. He played a critical role in the sale of Ovation to H. Lundbeck in 2009, after which he was promoted to head of U.S. business development and continued to lead identification and negotiation of licensing, acquisition and partnership transactions. Before joining the biopharma industry, he worked in the healthcare private equity group at Pequot Capital Management, and was also a financial analyst at Cowen & Company, an investment bank focused on healthcare and technology. Mr. Carlson received a Bachelor of Arts degree from Trinity College in Hartford, Connecticut.
About Kyn Therapeutics
Kyn Therapeutics is a clinical-stage
biotechnology company developing new immunometabolic therapies for
cancer. A growing body of research indicates that key metabolites can
exert broad suppressive or enhancing effects on the immune system
through a complex network of cellular interactions, providing targets
for new therapies that could significantly enhance patient response
rates to checkpoint inhibitors. Kyn Therapeutics is advancing
development candidates that modulate targets strongly implicated in
immunosuppression across a range of tumor types and via multiple immune
cell effects. In 2019, Kyn entered into a global strategic collaboration
with Celgene to develop novel immuno-oncology therapies. Kyn
Therapeutics is based in Boston, Massachusetts, and was launched by
OrbiMed Advisors and Atlas Venture. For more information, visit www.kyntherapeutics.com.
Follow us on Twitter and LinkedIn.
